Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-072036
Filing Date
2025-05-15
Accepted
2025-05-15 08:40:07
Documents
84
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q tsha-20250331.htm   iXBRL 10-Q 1892589
2 EX-31.1 tsha-ex31_1.htm EX-31.1 17804
3 EX-31.2 tsha-ex31_2.htm EX-31.2 17840
4 EX-32.1 tsha-ex32_1.htm EX-32.1 10236
5 EX-32.2 tsha-ex32_2.htm EX-32.2 10272
6 GRAPHIC img40492695_0.jpg GRAPHIC 139168
  Complete submission text file 0000950170-25-072036.txt   10197823

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tsha-20250331.xsd EX-101.SCH 1637487
87 EXTRACTED XBRL INSTANCE DOCUMENT tsha-20250331_htm.xml XML 1774448
Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39536 | Film No.: 25948976
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)